Browsing by Author "Baba, C."

Now showing 1 - 4 of 4

Citation - WoS: 3
Citation - Scopus: 3
Discriminative Ability of the Original and Short Form of the Activities-Specific Balance Confidence Scale and Its Individual Items for Falls in People With Multiple Sclerosis
(Springer Science and Business Media Deutschland GmbH, 2024) Abasıyanık, Z.; Kahraman, T.; Baba, C.; Sağıcı, Ö.; Ertekin, Ö.; Özakbaş, Serkan
Background: Balance confidence is an essential component of fall risk assessment in persons with multiple sclerosis (pwMS). Aims: The aims of this cross-sectional study were to 1) investigate the ability of the 16-item Activities-specific Balance Confidence scale (ABC-16), 6-item Activities-specific Balance Confidence scale (ABC-6), and each item of the ABC-16 for distinguishing fallers and 2) determine cutoff scores for these scales to discriminate fallers and non-fallers in pwMS. Methods: One hundred and fifty-six participants [fallers/non-fallers: 60 (38.5%)/96 (61.5%), median EDSS: 1.5] were enrolled. Balance confidence was assessed using the ABC-16 and ABC-6. The self-reported number of falls in the past three months was recorded. Descriptive assessments, including walking, balance, and cognition were performed. Logistic regression and receiver operating characteristic analyses were conducted to estimate the sensitivities and specificities of the ABC-16 and ABC-6. Results: Both the ABC-16 (AUC: 0.85) and ABC-6 (AUC: 0.84) had the discriminative ability for falls. Each item of the ABC-16 scale was a significantly related to falls [odds ratio (OR) range: 1.38 to 1.89]. Items 8 and 10 had the highest odds ratio (OR: 1.85; 95%CI: 1.47–2.33, OR: 1.89; 95%CI: 1.49–2.40; respectively). We found cutoff scores of ≤ 70 of 100 (sensitivity: 71.67, specificity: 86.46) and ≤ 65/100 (sensitivity: 76.67, specificity: 79.17) in discrimination between fallers and non-fallers for the ABC-16 and ABC-6, respectively. Conclusion: Both original and short forms of the ABC scale are an efficient tool for discriminating fallers and non-fallers in pwMS. Although all items are related to falls, outdoor walking activities have the strongest associations with falls than other items. © The Author(s) 2024.
Five-Year Outcomes in MS Patients Based on Type 2 and Type 3 Oligoclonal Band Patterns
(Wiley, 2025) Alizada, S.; Samadzada, U.; Yapici, N.; Cevik, S.; Zengin, E.; Baba, C.; Ozakbas, S.
Is Disease-Modifying Therapy Use in Multiple Sclerosis a Risk Factor During the Covid-19 Pandemic? a Large Cohort Study
(Pro Medicina Foundation, 2024) Ozakbas, S.; Baba, C.; Yavas, I.; Samadzade, U.; Ozdogar, A.T.
Objective: This study aims to investigate the relationship between disease-modifying therapies (DMTs) used in people with MS (pwMS) and the risk of COVID-19 in-fection. Methods: This longitudinal cohort study included the MS cohort of 3402 people followed for COVID-19 infection. The whole MS cohort was interviewed at least once for information about COVID-19. A semi-structured interview was developed and performed by a team consisting of a medical doctor, nurse, and physiotherapist. Clinical information was obtained from the patient's medical records. This study was approved by the Noninvasive Research Ethics Board (Date: 08.09.2021, Decision No: 2021/25-06). Results: Of the 487 pwMS infected with COVID-19, 35 reported reinfections. The major differences regarding DMT between pwMS with and without COVID-19 infection were observed for fingolimod, ocrelizumab, and azathioprine. Forty-three (8.9%) people experienced the COVID-19 infection severely or critically; 12 (37.5%) had MS treatment with ocrelizumab. Fifty percent of pwMS who were treated in intensive care (7/14 patients) and died (3/6 patients) were being treated with ocrelizumab. As a result of regression analysis, being younger and using di-methyl fumarate, fingolimod, ocrelizumab, and cladrib-ine DMTs were the main factors associated with having COVID-19 infection group. Conclusions: Current results show that disability due to MS and increased disease duration are not risk factors for COVID-19 infection, while age is negatively associated with contracting COVID-19 infection. These results show no relationship between the MS clinic and COVID-19 in-fection. We have found that using certain DMTs in pwMS increases the risk of contracting COVID-19 infection. © 2024 PRO MEDICINA Foundation,41 Published by PRO MEDICINA Foundation.
Citation - WoS: 3
Citation - Scopus: 3
Risk of Hepatitis B Virus Reactivation in People With Multiple Sclerosis Treated With Ocrelizumab: an Observational Study From Turkey
(Springer Science and Business Media Deutschland GmbH, 2024) Çelik, M.; Baba, C.; Irmak, Ç.; Özakbaş, Serkan; Avkan-Oğuz, V.
Background: The risk of hepatitis B virus (HBV) reactivation remains unclear in people with multiple sclerosis (MS) receiving ocrelizumab. We aimed to assess HBV seroprevalence and reactivation risk in MS patients on ocrelizumab and to evaluate the effectiveness of antiviral prophylaxis against HBV reactivation. Methods: In this single-center, cross-sectional study, 400 people with MS receiving ocrelizumab were screened for HBV at baseline and antiviral prophylaxis was implemented based on serological results. Patients were monitored for HBV reactivation, and outcomes were analyzed. Results: Among 56 (14%) patients who had serology compatible with occult or resolved HBV infection, 49 (85.7%) received antiviral prophylaxis regularly and had no HBV reactivation during the follow-up. Reactivation of HBV occurred in 2 out of 7 (28.6%) patients who did not receive antiviral prophylaxis and in one patient who did not adhere to the prophylaxis regimen. All patients with reactivation had anti-HBs levels below 100 mIU/mL and the median titer was significantly lower than the patients with no HBV reactivation (p = 0.034). Conclusion: This study highlights a 14% anti-HBc positivity, indicating a potential risk for HBV reactivation in people with MS receiving ocrelizumab. This suggests the importance of vigilant monitoring and the implementation of prophylactic measures. Our recommendation emphasizes antiviral prophylaxis, particularly for patients with low anti-HBs, and a pre-emptive strategy for others. © The Author(s) 2024.